Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued Cash Flow Analysts And A 20% Discount Rate.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals is developing a THC analog that offers the same benefits as THC without the negative side effects. Zacks Small-Cap Research values MIRA at $16.50 using discounted cash flow analysis with a 20% discount rate.
May 22, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals is developing a THC analog that offers the same benefits as THC without the negative side effects. Zacks Small-Cap Research values MIRA at $16.50 using discounted cash flow analysis with a 20% discount rate.
The development of a THC analog with the benefits of THC but without the negative side effects is a significant advancement. The valuation by Zacks Small-Cap Research at $16.50 using a 20% discount rate indicates strong potential for the company's stock price to rise in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100